| pubmed-article:2220622 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:2220622 | lifeskim:mentions | umls-concept:C0018802 | lld:lifeskim |
| pubmed-article:2220622 | lifeskim:mentions | umls-concept:C1522565 | lld:lifeskim |
| pubmed-article:2220622 | lifeskim:mentions | umls-concept:C0042523 | lld:lifeskim |
| pubmed-article:2220622 | lifeskim:mentions | umls-concept:C0012000 | lld:lifeskim |
| pubmed-article:2220622 | lifeskim:mentions | umls-concept:C0205307 | lld:lifeskim |
| pubmed-article:2220622 | lifeskim:mentions | umls-concept:C0597198 | lld:lifeskim |
| pubmed-article:2220622 | lifeskim:mentions | umls-concept:C0332281 | lld:lifeskim |
| pubmed-article:2220622 | lifeskim:mentions | umls-concept:C0205161 | lld:lifeskim |
| pubmed-article:2220622 | lifeskim:mentions | umls-concept:C0039155 | lld:lifeskim |
| pubmed-article:2220622 | pubmed:issue | 12 | lld:pubmed |
| pubmed-article:2220622 | pubmed:dateCreated | 1990-11-14 | lld:pubmed |
| pubmed-article:2220622 | pubmed:abstractText | Normal left ventricular systolic performance with impaired left ventricular diastolic filling may be present in a substantial number of patients with congestive heart failure (CHF). To evaluate the effect of oral verapamil in this subset, 20 men (mean age 68 +/- 5 years) with CHF, intact left ventricular function (ejection fraction greater than 45%) and abnormal diastolic filling (peak filling rate less than 2.5 end-diastolic volumes per second [edv/s]) were studied in a placebo-controlled, double-blind 5-week crossover trial. All patients underwent echocardiography to rule out significant valvular disease, and thallium-201 stress scintigraphy to exclude major active ischemia. Compared to baseline values, verapamil significantly improved exercise capacity by 33% (13.9 +/- 4.3 vs 10.7 +/- 3.4 minutes at baseline) and peak filling rate by 30% (2.29 +/- 0.54 vs 1.85 +/- 0.45 edv/s at baseline) (all p less than 0.05). Placebo values were 12.3 +/- 4.0 minutes and 2.16 +/- 0.48 edv/s, respectively (difference not significant for both). Improvement from baseline in an objective clinico-radiographic heart failure score (scale 0 to 13) was significantly greater with verapamil compared to placebo (median improvement in score: 3 vs 1, p less than 0.01). Mean ejection fraction and systolic blood pressure were unchanged from baseline; diastolic blood pressure and heart rate decreased to a small degree. Verapamil may have therapeutic efficacy in patients with CHF, preserved systolic function and impaired diastolic filling. | lld:pubmed |
| pubmed-article:2220622 | pubmed:language | eng | lld:pubmed |
| pubmed-article:2220622 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2220622 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:2220622 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2220622 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2220622 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:2220622 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:2220622 | pubmed:issn | 0002-9149 | lld:pubmed |
| pubmed-article:2220622 | pubmed:author | pubmed-author:BlackH RHR | lld:pubmed |
| pubmed-article:2220622 | pubmed:author | pubmed-author:ZaretB LBL | lld:pubmed |
| pubmed-article:2220622 | pubmed:author | pubmed-author:SchulmanD SDS | lld:pubmed |
| pubmed-article:2220622 | pubmed:author | pubmed-author:SouferRR | lld:pubmed |
| pubmed-article:2220622 | pubmed:author | pubmed-author:SetaroJ FJF | lld:pubmed |
| pubmed-article:2220622 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:2220622 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:2220622 | pubmed:volume | 66 | lld:pubmed |
| pubmed-article:2220622 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:2220622 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:2220622 | pubmed:pagination | 981-6 | lld:pubmed |
| pubmed-article:2220622 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:2220622 | pubmed:meshHeading | pubmed-meshheading:2220622-... | lld:pubmed |
| pubmed-article:2220622 | pubmed:meshHeading | pubmed-meshheading:2220622-... | lld:pubmed |
| pubmed-article:2220622 | pubmed:meshHeading | pubmed-meshheading:2220622-... | lld:pubmed |
| pubmed-article:2220622 | pubmed:meshHeading | pubmed-meshheading:2220622-... | lld:pubmed |
| pubmed-article:2220622 | pubmed:meshHeading | pubmed-meshheading:2220622-... | lld:pubmed |
| pubmed-article:2220622 | pubmed:meshHeading | pubmed-meshheading:2220622-... | lld:pubmed |
| pubmed-article:2220622 | pubmed:meshHeading | pubmed-meshheading:2220622-... | lld:pubmed |
| pubmed-article:2220622 | pubmed:meshHeading | pubmed-meshheading:2220622-... | lld:pubmed |
| pubmed-article:2220622 | pubmed:meshHeading | pubmed-meshheading:2220622-... | lld:pubmed |
| pubmed-article:2220622 | pubmed:meshHeading | pubmed-meshheading:2220622-... | lld:pubmed |
| pubmed-article:2220622 | pubmed:meshHeading | pubmed-meshheading:2220622-... | lld:pubmed |
| pubmed-article:2220622 | pubmed:meshHeading | pubmed-meshheading:2220622-... | lld:pubmed |
| pubmed-article:2220622 | pubmed:meshHeading | pubmed-meshheading:2220622-... | lld:pubmed |
| pubmed-article:2220622 | pubmed:meshHeading | pubmed-meshheading:2220622-... | lld:pubmed |
| pubmed-article:2220622 | pubmed:meshHeading | pubmed-meshheading:2220622-... | lld:pubmed |
| pubmed-article:2220622 | pubmed:meshHeading | pubmed-meshheading:2220622-... | lld:pubmed |
| pubmed-article:2220622 | pubmed:meshHeading | pubmed-meshheading:2220622-... | lld:pubmed |
| pubmed-article:2220622 | pubmed:year | 1990 | lld:pubmed |
| pubmed-article:2220622 | pubmed:articleTitle | Usefulness of verapamil for congestive heart failure associated with abnormal left ventricular diastolic filling and normal left ventricular systolic performance. | lld:pubmed |
| pubmed-article:2220622 | pubmed:affiliation | Department of Internal Medicine, West Haven Veterans Administration Medical Center, Connecticut. | lld:pubmed |
| pubmed-article:2220622 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:2220622 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:2220622 | pubmed:publicationType | Controlled Clinical Trial | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2220622 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2220622 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2220622 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2220622 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2220622 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2220622 | lld:pubmed |
